System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Franco Franceschini, MD

Rheumatology — Spedali Civili di Brescia, Italy

LeadR Profile

Franco Franceschini, MD Spedali Civili di Brescia Italy
1 632 ScienceLeadR Reputation 1632

Unlock

Register Login
Network Map

Rheumatology

Subspecialties: Internal Medicine - Immunology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Franco Franceschini graduated in Medicine and Surgery in 1983 at the University of Milan, where he specialized in Clinical Immunology and Allergology in 1986.

Medical Consultant in Clinical Immunology and Rheumatology at the Spedali Civili of Brescia, Italy (September 1986 - October 2019)

Visiting Fellow at the Bone Marrow Transplant Unit, University of California Los Angeles (UCLA), CA, USA (November 1985 - June 1986)

Visiting Fellow at the Department of Rheumatology, Royal Postgraduate Hammersmith Hospital, London, UK (November-December 1988)

Associate Professor of Rheumatology, Department of Clinical and Experimental Sciences, University of Brescia, Italy (December 2017 - April 2021). Full Professor since May 2021 (retired in Novembre 2025)

From December 2018 to December 2024: Director of the Specialization Program and the Specialization School in Rheumatology for the University of Brescia, Brescia, Italy

From November 2019 to November 2025: Director at the Rheumatology and Clinical Immunology Unit, ASST Spedali Civili di Brescia, Italy

He has worked in the field of rheumatology and autoimmunity with research interests in the pathogenesis, diagnosis and treatment of systemic autoimmune diseases as well as laboratory activities aimed at clinical research oriented to the study of autoantibodies as diagnostic and prognostic markers and to the validation of laboratory methods.

Organizations

Career arc: 1986 - 2026
Source: PubMed

University of Brescia

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 521

Citations

Citations: 12 203 1st author: 8 Last author: 85 Unique author: 0

Main journals

Ann Rheum Dis 126
Rheumatology (Oxford) 38
Clin Exp Rheumatol 37
J Rheumatol 20
Lupus 17

Best Journals

Eur Respir J 1
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Impact of Severe COVID-19 on Interstitial Lung Disease in Autoimmune Systemic Diseases.
sclerosis, lung, covid-19, pneumonia, lung diseases, scleroderma, systemic, lung diseases, interstitial		Respirol Case Rep20260
Macrophage activation syndrome in systemic lupus erythematosus and Still's disease: distinct phenotypes shaped by the underlying diseases.
macrophage activation, macrophages, phenotype, liver, rheumatic diseases, lupus erythematosus, systemic, hemolysis, therapeutics, lymphohistiocytosis, hemophagocytic, macrophage activation syndrome		Rheumatology (Oxford)20260
The convenience of family and community health nurses-led care for the treatment of rheumatic diseases with biological or targeted synthetic disease-modifying antirheumatic drugs. The experience of Valcamonica, Italy.
nurses, rheumatology, safety, pharmaceutical preparations, antirheumatic agents, arthritis, rheumatologists, nurses, community health, public health, rheumatic diseases, drug-related side effects and adverse reactions, therapeutics		Reumatismo20260
Mediterranean diet and health outcomes in idiopathic inflammatory myopathies.
muscular diseases, diet, mediterranean, diet, rheumatic diseases, myositis, demography		Rheumatology (Oxford)20260
The landscape of serum autoantibodies in lupus nephritis.
proteinuria, autoantibodies, serum, antibodies, lupus nephritis, biomarkers, signs and symptoms, histones, nephritis, autoimmunity		Autoimmun Rev20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Chair: 1

By phase:

N/A 5
Phase 2 1
Phase 3 1

By status:

Completed 3
Recruiting 2
Active not recruiting 1
Unknown 1

By type:

Observational 5
Interventional 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 4

Main Topics

Cohort/Consortium Investigators 5

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus Investigator Initiated Observational Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
NCT07215754 — quality of life, safety, incidence, pharmaceutical preparations, lupus erythematosus, systemic, drug-related side effects and adverse reactions, herpes zoster, therapeutics, steroids		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS